Millrose Properties, Inc. (MRP)
NYSE: MRP · Real-Time Price · USD
30.17
-0.37 (-1.21%)
Jul 31, 2025, 2:21 PM - Market open
Regulus Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts that cover Regulus Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $30.75, which forecasts a 1.92% increase in the stock price over the next year. The lowest target is $30 and the highest is $31.5.
Price Target: $30.75 (+1.92%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 15, 2025.
Analyst Ratings
The average analyst rating for Regulus Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|
| Strong Buy | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $28 → $32 | Strong Buy | Maintains | $28 → $32 | +4.41% | May 15, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | -0.56% | Apr 14, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | -17.14% | Feb 27, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.